BGNE Overview
Upcoming Projects (BGNE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BGNE)
-
A second look at the potential of BeiGene's anti–PD-1 antibody, Tislelizumab in gastric adenocarcinoma and the final analysis results of the RATIONALE-305 study presented at the ESMO 2023 conference.
Ticker: BGNE
Executed On: Oct 30, 2023 at 09:30 AM EDT -
A look at the potential of BeiGene's anti–PD-1 antibody, Tislelizumab in gastric adenocarcinoma and the final analysis results of the RATIONALE-305 study presented at the ESMO 2023 conference.
Ticker: BGNE
Executed On: Oct 24, 2023 at 09:00 AM EDT -
Discussing the current treatment landscape for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and the potential of Zanubrutinib(BRUKINSA®) and the phase 3 ALPINE trial.
Tickers: BGNE, AZN, ABBV
Executed On: Nov 04, 2022 at 09:15 AM EDT
Upcoming & Overdue Catalysts (BGNE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (BGNE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
